Fetal and early life antibiotics exposure and very early onset inflammatory bowel disease: A population-based study

Gut

Volumn 68, Issue 2, 2019, Pages 218-225

  Örtqvist, Anne K ^a   Lundholm, Cecilia ^a   Halfvarson, Jonas ^b   Ludvigsson, Jonas F ^a,c   Almqvist, Catarina ^a,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Örebro University   (Sweden)

^c ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

antibiotics; Crohn's colitis; epidemiology; inflammatory bowel disease; ulcerative colitis

Indexed keywords

NITROFURANTOIN; PENICILLIN V; PIVMECILLINAM; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DESCRIPTIVE RESEARCH; FEMALE; FETUS; GASTROENTERITIS; HUMAN; ICD-10; INFANT; LONGITUDINAL STUDY; MALE; MATERNAL EXPOSURE; POPULATION RESEARCH; PREDICTIVE VALUE; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SWEDEN; ULCERATIVE COLITIS; YOUNG ADULT; CHEMICALLY INDUCED; DRUG EFFECT; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; NEWBORN; PRESCHOOL CHILD; REGISTER;

ANTI-BACTERIAL AGENTS; CHILD, PRESCHOOL; FEMALE; FETUS; GASTROINTESTINAL MICROBIOME; HUMANS; INFANT; INFANT, NEWBORN; INFLAMMATORY BOWEL DISEASES; MALE; PREGNANCY; REGISTRIES; RISK FACTORS; SWEDEN;

EID: 85049136111     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2017-314352     Document Type: Article

References (56)

1. R osen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr 2015;169:1053-60.
2. G upta N, Bostrom AG, Kirschner BS, et al. Presentation and disease course in early-compared to later-onset pediatric Crohn's disease. Am J Gastroenterol 2008;103:2092-8.
3. Paul T, Birnbaum A, Pal DK, et al. Distinct phenotype of early childhood inflammatory bowel disease. J Clin Gastroenterol 2006;40:583-6.
4. Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 2005;146:35-40.
5. Bequet E, Sarter H, Fumery M, et al. Incidence and phenotype at diagnosis of veryearly-onset compared with later-onset paediatric inflammatory bowel disease: a population-based study [1988-2011]. J Crohns Colitis 2017;11:519-26.
6. Benchimol EI, Mack DR, Nguyen GC, et al. Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease. Gastroenterology 2014;147 803-13.
7. Satsangi J, Parkes M, Louis E, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 1996;14:199-202.
8. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001;357:1925-8.
9. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
10. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-24.
11. We E, D'Amato M, Halfvarson J. The history of genetics in inflammatory bowel disease. Annals of gastroenterology: quarterly publication of the Hellenic Society of Gastroenterology 2014;27:294-303.
12. Zhulina Y, Hahn-Strömberg V, Shamikh A, et al. Subclinical inflammation with increased neutrophil activity in healthy twin siblings reflect environmental influence in the pathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 2013;19:1725-31.
13. Parian A, Limketkai B, Koh J, et al. Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis. Gut 2017;66:1390-7.
14. Harries AD, Baird A, Rhodes J. Non-smoking: a feature of ulcerative colitis. Br Med J 1982;284:706.
15. T ysk C, Lindberg E, Järnerot G, et al. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988;29:990-6.
16. A ndersson RE, Olaison G, Tysk C, et al. Appendectomy is followed by increased risk of Crohn's disease. Gastroenterology 2003;124:40-6.
17. A ndersson RE, Olaison G, Tysk C, et al. Appendectomy and protection against ulcerative colitis. N Engl J Med 2001;344:808-14.
18. R adford-Smith GL, Edwards JE, Purdie DM, et al. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn's disease. Gut 2002;51:808-13.
19. Khalili H, Granath F, Smedby KE, et al. Association between long-term oral contraceptive use and risk of crohn's disease complications in a nationwide study. Gastroenterology 2016;150:1561-7.
20. Snapper SB. Very-Early-Onset Inflammatory Bowel Disease. Gastroenterol Hepatol 2015;11:554-6.
21. Ungaro R, Bernstein CN, Gearry R, et al. Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis. Am J Gastroenterol 2014;109:1728-38.
22. E kbom A. The Swedish Multi-generation Register. Methods Mol Biol 2011;675:215-20.
23. Wettermark B, Hammar N, Fored CM, et al. The new Swedish prescribed drug registeropportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726-35.
24. L udvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011;11:450.
25. L udvigsson JF, Otterblad-Olausson P, Pettersson BU, et al. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009;24:659-67.
26. A driaenssens N, Coenen S, Versporten A, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997-2009). J Antimicrob Chemother 2011;66:vi3-12.
27. Jakobsson GL, Sternegård E, Olén O, et al. Validating inflammatory bowel disease (IBD) in the Swedish National patient register and the Swedish quality register for IBD (SWIBREG). Scand J Gastroenterol 2017;52:216-21.
28. L udvigsson JF, Büsch K, Olén O, et al. Prevalence of paediatric inflammatory bowel disease in Sweden: a nationwide population-based register study. BMC Gastroenterol 2017;17:23.
29. C nattingius S, Ericson A, Gunnarskog J, et al. A quality study of a medical birth registry. Scand J Soc Med 1990;18:143-8.
30. G reenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology 1999;10:37-48.
31. C ard T, Logan RF, Rodrigues LC, et al. Antibiotic use and the development of Crohn's disease. Gut 2004;53:246-50.
32. Van Kruiningen HJ, Joossens M, Vermeire S, et al. Environmental factors in familial Crohn's disease in Belgium. Inflamm Bowel Dis 2005;11:360-5.
33. G earry RB, Richardson AK, Frampton CM, et al. Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol 2010;25:325-33.
34. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol 2010;105:2687-92.
35. Han DY, Fraser AG, Dryland P, et al. Environmental factors in the development of chronic inflammation: a case-control study on risk factors for Crohn's disease within New Zealand. Mutat Res 2010;690:116-22.
36. C astiglione F, Diaferia M, Morace F, et al. Risk factors for inflammatory bowel diseases according to the "hygiene hypothesis": a case-control, multi-centre, prospective study in Southern Italy. J Crohns Colitis 2012;6:324-9.
37. Virta L, Auvinen A, Helenius H, et al. Association of repeated exposure to antibiotics with the development of pediatric Crohn's disease-a nationwide, register-based finnish case-control study. Am J Epidemiol 2012;175:775-84.
38. Margolis DJ, Fanelli M, Hoffstad O, et al. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol 2010;105:2610-6.
39. Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut 2011;60:49-54.
40. Kronman MP, Zaoutis TE, Haynes K, et al. Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics 2012;130:e794-e803.
41. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol 2011;106:2133-42.
42. G evers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in newonset Crohn's disease. Cell Host Microbe 2014;15:382-92.
43. I mhann F, Vich Vila A, Bonder MJ, et al. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut 2018;67.
44. Halfvarson J, Brislawn CJ, Lamendella R, et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol 2017;2:17004.
45. Koren O, Goodrich JK, Cullender TC, et al. Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell 2012;150:470-80.
46. Munyaka PM, Eissa N, Bernstein CN, et al. Antepartum antibiotic treatment increases offspring susceptibility to experimental colitis: a role of the gut microbiota. PLoS One 2015;10:e0142536.
47. C ollado MC, Rautava S, Aakko J, et al. Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid. Sci Rep 2016;6:23129.
48. N ogacka A, Salazar N, Suárez M, et al. Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates. Microbiome 2017;5:93.
49. A zad MB, Konya T, Persaud RR, et al. Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study. BJOG 2016;123:983-93.
50. Jauréguy F, Carton M, Panel P, et al. Effects of intrapartum penicillin prophylaxis on intestinal bacterial colonization in infants. J Clin Microbiol 2004;42:5184-8.
51. R autava S, Collado MC, Salminen S, et al. Probiotics modulate host-microbe interaction in the placenta and fetal gut: a randomized, double-blind, placebocontrolled trial. Neonatology 2012;102:178-84.
52. Bernstein CN, Burchill C, Targownik LE, et al. Maternal infections that would warrant antibiotic use antepartum or peripartum are not a risk factor for the development of ibd: a population-based analysis. Inflamm Bowel Dis 2017;23:635-40.
53. G omollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of crohn's disease 2016: Part 1: diagnosis and medical management. J Crohns Colitis 2017;11:3-25.
54. A hlén KM, Örtqvist AK, Gong T, et al. Antibiotic treatment and length of hospital stay in relation to delivery mode and prematurity. PLoS One 2016;11:e0164126.
55. Hellman J O-LB, Bengtsson B. Swedres-Svarm GC Use of antimicrobials and occurrence of antimicrobial resistance in Sweden Secondary SWEDRES-SVARM 2016. Use of antimicrobials and occurrence of antimicrobial resistance in Sweden, Solna, Sweden: Public Health Agency of Sweden and National Veterinary Institute 2016 http://www. sva. se/ globalassets/ redesign2011/ pdf/ om_ sva/ publikationer/ swedres_ svarm2016. pdf.
56. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother 2002;49:897-903.